학술논문
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
Document Type
journal article
Author
Source
Journal of Clinical Oncology; 10/1/2008, Vol. 26 Issue 28, p4563-4571, 9p
Subject
Language
ISSN
0732183X